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Background: The hemostatic properties of tranexamic acid (TXA) are well described,
but the immunological effects of TXA administration after traumatic injury have not
been thoroughly examined. We hypothesized TXA would reduce monocyte activation
in bleeding trauma patients with severe injury.
Methods: This was a single center, double-blinded, randomized controlled trial
(RCT) comparing placebo to a 2 g or 4 g intravenous TXA bolus dose in trauma
patients with severe injury. Fifty patients were randomized into each study group. The
primary outcome was a reduction in monocyte activation as measured by human
leukocyte antigen-DR isotype (HLA-DR) expression on monocytes 72 h after TXA
administration. Secondary outcomes included kinetic assessment of immune and
hemostatic phenotypes within the 72 h window post-TXA administration.
Results: The trial occurred between March 2016 and September 2017, when data
collection ended. 149 patients were analyzed (placebo, n = 50; 2 g TXA, n = 49;
4 g TXA, n = 50). The fold change in HLA-DR expression on monocytes [reported as
median (Q1–Q3)] from pre-TXA to 72 h post-TXA was similar between placebo [0.61
(0.51–0.82)], 2 g TXA [0.57 (0.47–0.75)], and 4 g TXA [0.57 (0.44–0.89)] study groups
(p = 0.82). Neutrophil CD62L expression was reduced in the 4 g TXA group [fold change:
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0.73 (0.63–0.97)] compared to the placebo group [0.97 (0.78–1.10)] at 24 h post-TXA
(p = 0.034). The fold decrease in plasma IL-6 was significantly less in the 4 g TXA group
[1.36 (0.87–2.42)] compared to the placebo group [0.46 (0.19–1.69)] at 72 h post-TXA
(p = 0.028). There were no differences in frequencies of myeloid or lymphoid populations
or in classical complement activation at any of the study time points.
Conclusion: In trauma patients with severe injury, 4 g intravenous bolus dosing of
TXA has minimal immunomodulatory effects with respect to leukocyte phenotypes and
circulating cytokine levels.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02535949.
Keywords: tranexamic acid, monocyte activation, immunology, hemostasis, trauma
INTRODUCTION
In the United States (US), trauma is the leading cause of
death in the population from 1 to 46 years of age (1), and
each year in the United States there are an estimated 30,000
preventable deaths after traumatic injury due to hemorrhage (2).
Trauma-induced coagulopathy (TIC) occurs in approximately
25% of injured patients (3–5). One of the primary mechanisms
of TIC is hyperfibrinolysis (6). Observational data in multiple
studies indicate that hyperfibrinolysis following traumatic injury
is independently associated with an increased risk of mortality
(7–10). Tranexamic acid (TXA), an antifibrinolytic agent, has
become a standard of care in severely bleeding trauma patients
(11–13). This practice is primarily based on the results of
the landmark Clinical Randomization of an Antifibrinolytic in
Significant Hemorrhage 2 (CRASH-2) trial, which demonstrated
TXA administration within 3 h of injury increased survival
in patients with significant hemorrhage (14), and on results
from the Clinical Randomization of an Antifibrinolytic in
Significant Hemorrhage 3 (CRASH-3) trial showing improved
survival for patients with mild to moderate brain injury (15).
However, certain aspects of the CRASH-2 results suggest that
the effect of TXA in trauma patients may not be purely due to
the inhibition of fibrinolysis. In particular, the data indicating
increased mortality due to bleeding when TXA was given after 3 h
(16) suggest that TXA may have additional biologic properties in
this population.
Tranexamic acid is a lysine analog which irreversibly binds
plasminogen thereby inhibiting fibrin binding, thus decreasing
fibrinolysis and increasing clot stability (17, 18). Through
this mechanism, TXA reduces bleeding. However, plasmin
is an enzyme with a broad range of substrates affecting
both hemostatic and immune function (19, 20). Plasmin
promotes monocyte (21, 22), macrophage (23), and dendritic
cell (24) migration through proteolytic mechanisms and through
Abbreviations: CRASH-2, clinical randomization of an antifibrinolytic in
significant hemorrhage; fMLF, N-formylmethionyl-leucyl-phenylalanine; IDS,
investigational drug service; MA, maximal amplitude; RBC, red blood cells; RCT,
randomized controlled trial; SAS, statistical analysis software; TBI, traumatic
brain injury; TIC, trauma induced coagulopathy; TXA, tranexamic acid; Wash U,
Washington University in St. Louis; WB, whole blood.
induction of actin polymerization. Plasmin has also been
shown to potentiate phagocytosis in dendritic cells (25) and
macrophages (26). Moreover, plasmin is a potent activator of
monocytes via NF-κB (27), JAK/STAT (28), and 5-lipoxygenase
signaling (29, 30). These pathways are associated with the
production of proinflammatory cytokines (such as TNFα and
IL-1β) (27), MCP-1 release (28), and leukotriene synthesis (31),
respectively. Lastly, plasmin is a potent activator of complement
[complement component 3 (C3) and complement component
5 (C5) cleavage (32, 33)], and complement itself is immune
activating (34). To this end, the use of anti-fibrinolytics which
reduce plasmin function may also result in a dampening of
the inflammation and immune functions associated with the
pathophysiology of traumatic injury.
Interestingly, in vivo studies in small rodents have
demonstrated TXA is anti-inflammatory in polytrauma (35), TBI
(36), and ischemia reperfusion injury (37) models. In humans,
the inflammatory nature of TXA is less well defined. In one study
of orthopedic surgery patients, intravenous TXA administration
both before and after surgery led to increased levels of circulating
proinflammatory molecules, such as TNF-α, IL-1β, and IL-6 (38).
Conversely, in another cohort of orthopedic surgery patients
followed up to 48 h, it was found that an increased number of
post-operative oral doses of TXA suppressed IL-6 levels (39).
Moreover, prophylactic TXA use in cardiac surgery patients was
shown to have an “immune-enhancing” effect, as leukocytes
from patients receiving TXA had decreased expression of
immunosuppressive surface markers (LAP and PD-L1), and
increased expression of immune-activating markers (CD83 and
CCR7) (40). This study also showed that IL-1β, but not other
proinflammatory cytokines, was significantly increased in the
TXA group compared to the placebo group. These contrasting
immune phenotypes of TXA in rodent trauma models compared
to humans with surgical bleeding highlights the need for
further evaluation of the immunomodulatory effects of TXA in
trauma patients.
Based on the role of plasmin as an immune activator,
and the inhibition of plasmin by TXA, we hypothesized that
TXA would (i) reduce monocyte and complement activation
and (ii) decrease fibrinolysis in a dose-dependent manner in
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traumatically injured patients. To test these hypotheses, we
performed a double-blinded randomized controlled trial (RCT)
comparing placebo to 2 g or 4 g intravenous (i.v.) bolus TXA
doses to examine the immunological consequences of TXA
administration in severely injured patients. Given the pleiotropic
effects of plasmin on immune and hemostatic function, we
also performed extensive exploratory immune phenotyping on
enrolled subjects.
MATERIALS AND METHODS
Study Design and Treatment Protocols
This study was a prospective single-center double-blinded RCT,
and was performed at Wash U, a tertiary care center. The trial was
approved by the US FDA (IND 125420), and by the Institutional
Review Board at Wash U, and the United States Army Medical
Research and Materiel Command Human Research Protections
Office. The trial was performed with exception from informed
consent including community consultation with delayed patient
or legally authorized representative consent. In addition, the
trial was overseen by an independent research monitor and
an external data and safety monitoring board. This study
was conducted in accordance with Good Clinical Practice
guidelines, the Declaration of Helsinki, and Title 21 of the
Code of Federal Regulations. The full clinical trial protocol
can be found in the Supplementary Material. The trial is
registered at ClinicalTrials.gov (NCT02535949) and the trial is
closed for accrual.
Patients
Trained research staff consecutively screened all patients
requiring a Level I trauma activation at a single American College
of Surgeons-verified Level I academic trauma center for potential
inclusion in the study. Patients were eligible for inclusion if
they were 18 years of age or older, sustained a traumatic injury
which required them to receive at least one unit of red blood
cells (RBC) or required an emergent operation for possible
bleeding control, and were able to receive the study medication
(TXA or placebo) within 2 h of time of injury. Patients were
excluded if they had a known past medical history of thrombotic
events, seizures, or subarachnoid hemorrhage, or met other
exclusion criteria (the full list of exclusion criteria can be found
in Supplementary Table S1).
Randomization and Masking
For patient randomization, SAS programs were written to
generate the randomization order and the programs were
implemented online using REDCap. Randomization was blocked
using random block sizes. Concealment was accomplished by
virtue of the online procedures that prevented group assignment
from being known until the actual subject was ready to be
randomized. There was no stratification. With the exception of
the investigational drug service (IDS) staff preparing study drug,
all participants, study team members, and investigators were
blinded to the treatment arms. The IDS maintained the blind by
placing study drug or placebo in a syringe that was labeled only
with the TXA study number, and the study number was linked
to the randomization group maintained only by IDS. The volume
and color of the fluid in the syringe were identical for each study
drug or placebo. Coordinators verified the TXA study number
used for each subject in a log prior to dosing.
Procedures and Clinical Data Collection
After patient enrollment, demographics, injury characteristics,
baseline physiological parameters, surgical procedures,
concomitant medications, and blood product(s) administration
were collected. Eligible patients were randomized via fixed-
allocation computer randomization to receive either placebo,
2 gram (g) of TXA, or 4 g of TXA in 40 milliliters (mL) of normal
saline i.v. over 10 min. The doses of 2 g and 4 g i.v. were based
on the TXA bolus dosing ranges from previous trials examining
TXA that range from 15 to 100 milligram (mg)/kilogram (kg)
i.v. bolus (40). A 2 and 4 g dose of TXA would be 25 mg/kg and
50 mg/kg, respectively, in an 80 kg patient. A 100 mg/kg dose of
TXA in a 80 kg patient would be equal to an 8 g i.v. dose. A single
bolus dose was implemented to accommodate a dosing regimen
that would be simpler to implement in United States military
deployed settings that are often in austere environments. Soft
tissue oxygen tension was measured with each blood draw using
InSpectra StO2 Spot Check device (Hutchinson Technology,
Hutchinson, MN, United States). A baseline blood draw was
performed prior to administration of study drug (0 h, T0)
and at pre-specified intervals after study drug administration:
6 h (T6), 24 h (T24), and 72 h (T72). Patients were followed
until discharge or study day 28, whichever came first. Study
participants were assessed daily for length of stay (LOS) in
the Intensive Care Unit (ICU), ventilator days, mortality,
thromboembolic events, abnormal clinical laboratory values, and
safety and adverse events.
Outcomes
The primary trial outcome was a reduction in monocyte
activation, measured by Human Leukocyte Antigen-DR isotype
(HLA-DR) expression on monocytes, from zero to 72 h after
TXA administration. Reduction in HLA-DR expression was
chosen as the primary outcome as it has been associated
with clinical outcomes, such as the risk of sepsis, in patients
with traumatic injury (41). Secondary outcomes included other
measures of immune function, hemostasis, and endothelial
function. Secondary clinical outcomes included multiple organ
dysfunction syndrome (MODS), thromboembolic events, and
mortality at 28 days. MODS scores were assessed daily by
calculation of the Marshall Score (42).
Immunophenotyping
For immunophenotyping, blood was collected in K2EDTA
Vacutainer Blood Collection Tubes. Blood was fixed within
2 h of sample collection by mixing 1.25 mL whole blood
(WB) with 1.75 mL Proteomic Stabilizer (Smart Tube Inc., San
Carlos, CA, United States) and incubating for 10 min at room
temperature (RT). Subsequently, samples were frozen at −80◦C.
Flow cytometric immunophenotyping was performed in batch
analysis, processing samples from all time points of two to four
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FIGURE 1 | TAMPITI Patient Screening, Enrollment, Randomization, and Analysis Diagram. This Consolidated Standards of Reporting Trials (CONSORT) diagram
displays the number of patients screened for eligibility, excluded based on not meeting study inclusion criteria, patients enrolled and randomized, and the patients
analyzed per study group.
patients simultaneously. Samples were thawed, subjected to RBC
lysis and washing steps per manufacturer’s recommendations.
Cells were incubated with Fc receptor blocking reagent (TruStain
FcX, Biolegend, San Diego, CA, United States) and stained with
fluorochrome-conjugated antibodies (Panels 1, 2, and 3; see
Supplementary Table S2). Samples were acquired on an LSR
Fortessa flow cytometer using Diva software (both from BD
Biosciences, San Jose, CA, United States) and analyzed with the
FlowJo v10.2 software (Treestar, Ashland, OR, United States).
Analysis of the individual peripheral blood leukocyte subsets
was done as specified by gating strategies in Supplementary
Table S3. Cell concentrations in stained samples were determined
by adding counting beads to the samples immediately before
flow cytometric acquisition (123count eBeads, eBioscience, San
Diego, CA, United States). Cell concentrations in samples
were calculated per manufacturer’s directions and were used to
determine the cell counts per mL of WB.
Soluble Inflammatory Mediator Levels
and Complement Activation Assessment
Soluble inflammatory mediators (cytokines and chemokines)
were analyzed in the Immunomonitoring Laboratory (Wash U)
using the 384-well Human High Sensitivity T cell Milliplex assay,
which detects 21 cytokines and chemokines (HSTCMAG384-
PX21; EMD Millipore, Billerica, MA, United States).
Platelet-poor plasma (PPP) samples (isolation protocol in
Supplementary Methods) were thawed on ice, mixed, then
centrifuged at 10,000g for 5 min at 4◦C to remove particulates.
PPP was then diluted 1:4 in assay buffer and tested in duplicate
as per the manufacturer’s recommendations. A FLEXMAP3D
Luminex analyzer was used to determine median fluorescence
intensity (MFI) for 50 beads per analyte. MFIs were compared
to the standard curves that generated pg/mL values for each
analyte using a 5-parameter logistic regression analysis program
(Milliplex Analyst 5.1.0, Vigene Tech Inc., Carlisle, MA,
United States). For total hemolytic complement activation
measurement (CH50, Iu/mL), PPP was thawed at RT and
assessed using a CH50 assay (#A018, Quidel, San Diego, CA,
United States) per manufacturer’s suggested protocol.
Hemostatic and Endothelial Assessment
Stored PPP samples from each patient were assessed for
hemostatic function. Specifically, clotting in response to kaolin
activation via thromboelastography (TEG) was performed
with PPP (43–49) according to manufacturer’s protocol (#07-
004, Haemonetics, Braintree, MA, United States) using a
TEG5000. R time (min), K time (min), alpha angle (◦), and
maximum amplitude (millimeters, mm) were reported. Both
mechanical and immunoturbidimetric methods via STA-
Compact Max or STA-R were used to measure PPP levels
of fibrinogen (FIB, mg/deciliter (dL); STA-FIBRINOGEN 5,
#00674, Diagnostica Stago, Parsippany, NJ, United States), von
Willebrand factor (VWF,%; STA LIATEST VWF:AG, #00518,
Diagnostica Stago), and D-dimer (micrograms (µg)/mL; STA
LIATEST D DI, #00515, Diagnostica Stago). Manufacturer’s
protocols were followed for FIB, VWF, and D-dimer. Enzyme-
linked immunosorbent assays (ELISAs) were used for the
following measurements, following the manufacturer’s suggested
protocol for each assay: thrombin-antithrombin complex
(TAT, #OWMG15, Siemens, Munich, Germany), tissue-type
plasminogen activator (tPA, #BMS258-2, Thermo Fisher
Scientific, Carlsbad, CA, United States), prothrombin fragment
1 + 2 (PF1.2, #027756, US Biological Life Sciences, Salem, MA,
United States), kininogen (KNG1, #KA1040, Novus Biologicals,
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TABLE 1 | Patient demographics, baseline characteristics, and clinical outcomes in each study group. Values are reported as median (Q1–Q3) unless
otherwise indicated.
Variable n Placebo n 2 g TXA n 4 g TXA p-value
Demographics
Age (years) 50 27.0 (22.0− 34.0) 49 26.0 (22.0− 40.0) 50 31.0 (25.0− 44.0) 0.13
Male [n, (%)] 50 45 (90.0%) 49 44 (90.0%) 50 42 (84.0%) 0.58
BMI 47 26.5 (22.8− 30.0) 46 25.4 (23.1− 29.5) 50 25.2 (23.7− 29.9) 0.34
Hispanic [n, (%)] 50 1 (2.00%) 49 2 (4.08%) 50 1 (2.00%) 0.76
African American [n, (%)] 49 44 (88.0%) 49 42 (85.7%) 49 43 (86.0%) 0.94
Injury to admission time (min) 50 30.0 (22.0− 39.0) 49 28.0 (20.0− 35.0) 50 28.0 (21.0− 38.0) 0.44
Injury to T0 blood sample (min) 50 57.5 (47.0− 74.0) 49 67.0 (48.0− 85.0) 50 60.0 (50.0− 82.0) 0.46
Injury to TXA administration (min) 50 95.5 (81.0− 103) 49 97.0 (85.0− 111) 50 96.5 (77.0− 106) 0.48
Injury severity
Penetrating Injury [n, (%)] 50 41 (82.0%) 49 38 (77.6%) 50 39 (78.0%) 0.83
Heart Rate (BPM) 49 97.0 (83.0− 120) 49 102 (90.0− 128) 50 100.5 (80.0− 117.0) 0.39
SBP (mmHg) 48 120 (98.0− 141) 49 119 (90.0− 142) 50 118 (98.0− 135) 0.98
SBP ≤ 90 mmHg [n, (%)] 49 8 (16.0%) 49 14 (28.6%) 50 7 (14.0%) 0.15
Temperature (◦C) 26 36.5 (35.8− 36.7) 21 36.5 (36.3− 36.7) 27 36.5 (36.3− 36.7) 0.17
GCS 50 15.0 (12.0− 15.0) 49 15.0 (11.0− 15.0) 50 15.0 (14.0− 15.0) 0.26
GCS ≤ 8 [n, (%)] 50 10 (20.0%) 49 12 (24.5%) 50 5 (10.0%) 0.16
NIRS (%) 26 87.5 (80.0− 90.0) 22 88.0 (84.0− 91.0) 20 87.5 (78.0− 93.0) 0.50
Creatinine (mg/dL) 33 1.30 (1.13− 1.61) 45 1.17 (1.03− 1.37) 48 1.22 (0.99− 1.39) 0.03
Platelet count (X106/mL) 50 215 (179− 273) 48 229 (166− 287) 47 217 (185− 258) 0.78
Fibrinogen (mg/dL) 45 180 (146− 251) 39 190 (143− 222) 44 185 (149− 245) 0.41
INR 46 1.12 (1.05− 1.23) 43 1.12 (1.06− 1.26) 44 1.10 (1.03− 1.16) 0.18
Lactate (mmol/L) 44 4.70 (3.50− 8.80) 43 4.50 (3.30− 8.70) 40 4.45 (2.70− 7.15) 0.57
APACHE II 50 19.0 (10.0− 27.0) 49 16.0 (11.0− 24.0) 50 16.0 (9.00− 25.0) 0.74
ISS 46 19.5 (14.0− 34.0) 43 22.0 (16.0− 34.0) 44 19.0 (14.0− 29.0) 0.47
AIS Head ≥ 3 [n, (%)] 50 7 (14.0%) 49 1 (2.00%) 50 7 (14.0%) 0.08
AIS Face ≥ 3 [n, (%)] 50 0 (0%) 49 0 (0%) 50 0 (0%) n/a
AIS Chest ≥ 3 [n, (%)] 50 22 (44.0%) 49 27 (55.1%) 50 20 (40.0%) 0.30
AIS Abdomen ≥ 3 [n, (%)] 50 29 (58.0%) 49 28 (57.1%) 50 25 (50.0%) 0.68
AIS Extremity ≥ 3 [n, (%)] 50 20 (40.0%) 49 22 (44.9%) 50 22 (44.0%) 0.87
AIS External ≥ 3 [n, (%)] 50 1 (2.00%) 49 1 (2.04%) 50 4 (8.00%) 0.22
Pre-TXA blood product administration - Number transfused and volume received
RBC Recipients [n, (%)] 50 36 (72.0%) 49 36 (73.5%) 50 34 (68.0%) 0.82
RBC Volume (mL/Kg) 47 8.73 (0.00− 31.2) 46 13.4 (0.00− 31.78) 50 9.50 (0.00− 36.5) 0.79
Plasma Recipients [n, (%)] 50 20 (40.0%) 49 25 (51.0%) 50 24 (48.0%) 0.52
Plasma Volume (mL/Kg) 47 0.00 (0.00− 16.0) 46 0.00 (0.00− 15.9) 50 0.00 (0.00− 18.8) 0.84
Platelet Recipients [n, (%)] 50 17 (34.0%) 49 18 (36.7%) 50 13 (26.0%) 0.49
Platelet Volume (mL/Kg) 47 0.00 (0.00− 2.53) 46 0.00 (0.00− 2.42) 47 0.00 (0.00− 2.00) 0.69
Cryo Recipients [n, (%)] 50 0 (0%) 49 1 (2.04%) 50 0 (0%) 0.36
Cryo Volume (mL/Kg) 47 0.00 (0.00− 0.00) 46 0.00 (0.00− 0.00) 50 0.00 (0.00− 0.00) 0.35
P-values reported are for comparisons between all three study groups as described in the methods. BMI, body mass index; TXA, tranexamic acid; BPM, beats per minute;
SBP, systolic blood pressure; mmHg, millimeters mercury; GCS, glasgow coma score; NIRS, near-infrared spectroscopy; INR, international normalized ratio APACHE II,
acute physiology, age, chronic health evaluation II; ISS, injury severity score; AIS, abbreviated injury scale; Pre-TXA, prior to TXA administration; RBC, red blood cell; Cryo,
cryoprecipitate.
Littleton, CO, United States), plasmin/alpha-2-antiplasmin (PAP,
#603, BioMedica Diagnostics, Windsor, Nova Scotia, Canada),
syndecan-1 (SDC1, #EHSDC1, Thermo Fisher Scientific).
Statistics and Power Calculations
This study was powered to assess the effect of TXA on
HLA-DR expression on monocytes. A 10% decrease in the
frequency of CD14+/HLA-DR+ monocytes was considered by
the investigators to be potentially clinically relevant. Using a
two-tailed alpha of 0.05, a power of 0.90, and accounting for
a 20% drop-out rate, we estimated 47 patients per arm. To
account for missing data, we aimed to enroll 50 patients per
study group for a total of 150 patients. No interim analysis was
planned, and the study was stopped upon reaching the planned
sample size in all three study groups. Baseline demographics, and
injury, physiological, and outcome variables were described and
compared for participants in each study group. Percentages were
used to describe categorical variables, and Pearson chi-square
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TABLE 2 | Blood product usage and clinical outcomes in all three treatment groups.
Variable n Placebo n 2 g TXA n 4 g TXA p-value
Outcomes
ICU admission [n, (%)] 50 37 (74.0%) 49 36 (73.5%) 50 38 (76.0%) 0.96
Mechanical ventilation [n, (%)] 50 30 (60.0%) 48 28 (58.3%) 49 30 (61.2%) 0.96
ICU-free Days 50 27.3 (17.4− 28.6) 45 27.1 (24.0− 29.4) 49 27.1 (24.3− 29.0) 0.77
Max MODS in 7 days 49 4.00 (1.00− 7.00) 49 4.00 (1.00− 6.00) 50 4.00 (1.00− 8.00) 0.79
Seizure [n, (%)] 49 0 (0.00%) 44 1 (2.27%) 48 2 (4.17%) 0.42
TE [n, (%)] 50 6 (12.0%) 49 13 (26.5%) 50 16 (32.0%) 0.05
28-day mortality [n, (%)] 49 6 (12.2%) 44 5 (11.4%) 48 4 (8.33%) 0.81
Post-TXA blood product administration - Number transfused and volume received
RBC Recipients [n, (%)] 50 22 (44.0%) 49 25 (51.0%) 50 24 (46.0%) 0.78
RBC Volume (mL/Kg) 47 0.00 (0.00− 13.2) 46 0.00 (0.00− 11.4) 50 0.00 (0.00− 19.3) 0.92
Plasma Recipients [n, (%)] 50 17 (34.0%) 49 12 (24.5%) 50 15 (30.0%) 0.58
Plasma Volume (mL/Kg) 47 0.00 (0.00− 6.83) 46 0.00 (0.00− 0.00) 50 0.00 (0.00− 6.73) 0.99
Platelet Recipients [n, (%)] 50 15 (30.0%) 49 13 (26.5%) 50 13 (26.0%) 0.89
Platelet Volume (mL/Kg) 47 0.00 (0.00− 2.96) 46 0.00 (0.00− 0.00) 50 0.00 (0.00− 2.42) 0.85
Cryo Recipients [n, (%)] 50 7 (14.0%) 49 7 (14.3%) 50 8 (16.0%) 0.95
Cryo Volume (mL/Kg) 47 0.00 (0.00− 0.00) 46 0.00 (0.00− 0.00) 50 0.00 (0.00− 0.00) 0.43
Values are reported as median (Q1-Q3) unless otherwise indicated. P-values reported are for comparisons between all three study groups as described in the section
“Materials and Methods.” ICU, intensive care unit; RBC, red blood cell; Cryo, cryoprecipitate; Post-TXA, after TXA administration; MODS, multiple organ dysfunction
score; TE, thromboembolic event.
or Fisher’s Exact tests were used for tests for differences among
groups. Continuous and ordinal variables were described by
medians and interquartile ranges and differences tested with
Kruskal–Wallis tests. Systolic blood pressure, Glasgow Coma
Score (GCS), abbreviated injury score (AIS) and injury severity
score (ISS), were dichotomized and analyzed with chi-squared
tests. For immune and hemostatic phenotyping laboratory-based
tests, results at a given time point (T0, T6, T24, and T72) between
treatment groups (placebo, 2 g TXA, 4 g TXA) were compared
by non-parametric analysis of variance (ANOVA; Kruskal–
Wallis test), and if found significant, further analyzed using a
Dunn’s multiple comparison test to determine which groups were
significantly different from the placebo group. For all kinetic
analyses, only patients with full sets of data [samples at each of the
four time points (T0, T6, T24, and T72)] were analyzed in order
to accurately assess changes over time. To do these analyses, a fold
change methodology was employed, whereby values acquired
at T6, T24, and T72 were normalized to baseline (T0) values
for all patients with samples available at all four time points
(n of patients for each graph and paired analysis are delineated
in figure legends). Specifically, fold change was calculated as
[(frequency/MFI/concentration of a given population/analyte at
the given time | | T6,T24,T72| |)÷ (frequency/MFI/concentration
of the same population/analyte at T0)]. For analyses pertaining
to data from all patients with available samples, results at a
given time point (T0, T6, T24, and T72) between treatment
groups (placebo, 2 g TXA, 4 g TXA) were compared by
non-parametric analysis of variance (ANOVA; Kruskal–Wallis
test) and are located in Supplementary Tables S4–S6. SAS (v9.4
for Windows, SAS Institute Inc., Cary, NC, United States) and
Prism 8 (for Windows 64-bit (v8.1.0), GraphPad Software, San
Diego, CA, United States) were used for statistical analyses
and correlation matrices calculations and visual representations.
Principal component analysis (PCA) was performed using R
version 3.6.2 (R Core Team, 2019, R Foundation for Statistical
Computing, Vienna, Austria), stats (used prcomp() function;
3.6.2, R Core Team, 2019), and ggplot2 (3.3.0, Wickham H, 2016)
packages. Code used can be found in Supplementary Methods.
RESULTS
There were 150 patients enrolled in the trial between March 2016
and September 2017. One patient was withdrawn from the 2 g
TXA group when it was determined that they were less than
18 years of age and in violation of eligibility criteria. As a result,
149 patients were included in the analysis, with 50 patients in the
placebo group, 49 patients in the 2 g TXA group, and 50 patients
in the 4 g TXA group (Figure 1 and Supplementary Table S1).
There were no differences in baseline patient demographics or
in measures of severity of injury between the three study groups
(Table 1). The time in minutes from injury to administration
of TXA was similar between placebo, 2 g TXA, and 4 g TXA
study groups [median (Q1–Q3): 95.5 min (81.0–103) vs. 97.0 min
(85.0–111) vs. 96.5 min (77.0–106), respectively; p = 0.47]. The
median time in minutes from injury to T0 immune assessment
was 57.5 (46.8–74.3) for placebo, 67.0 (46.5–85.0) for 2 g TXA,
and 60.0 (50.0–82.8) for the 4 g TXA treatment group (Table 1).
The amount of blood products given before TXA administration
was also similar between the three study groups (Table 1). There
were no differences in clinical outcomes, to include mortality, or
the amount of blood products given after TXA administration
between the three study groups (Table 2). However, there was
a difference in the incidence of thromboembolic events (TE)
between study groups that approached significance [placebo,
12.0%; 2 g (26.5%); 4 g (32.0%)], (p = 0.05; Table 2).
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FIGURE 2 | TXA administration does not alter monocyte expression of
HLA-DR. For all kinetic data, fold change was calculated as
[(frequency/MFI/concentration of a given population/analyte at the given time |
| T6,T24,T72| |) ÷ (frequency/MFI/concentration of the same
population/analyte at T0)]. Data are displayed as line graphs (fold change,
median + IQR). The dashed line placed at y = 1 represents T0, or baseline.
Placebo, n = 29; 2 g TXA, n = 24; 4 g TXA, n = 25. Statistical differences
between the 4 g TXA and placebo groups at each given time point, as
calculated via Kruskal-Wallis, are noted as follows: p > 0.05, not significant
and not denoted on the graphical representation. (A) The frequency of
CD14+CD16- monocytes found in total peripheral blood leukocytes at T0 in
all three treatment groups; data are represented as individual points with
median + IQR for error bars. (B) Fold change in frequency of CD14+CD16-
monocytes found in total peripheral blood leukocytes over the study period of
72 h. (C) HLA-DR MFI on CD14+CD16- monocytes in all three treatment
groups at T0. (D) Fold change in HLA-DR MFI on CD14+CD16- monocytes
over the study period of 72 h.
At T0, there was no difference in the frequency of circulating
CD14+CD16− monocytes between the three treatment groups
(Figure 2A). In addition, by 72 h post-TXA administration, the
frequency of CD14+CD16− monocytes in all three treatment
groups had increased roughly 1.4-fold (median (Q1-Q3): placebo,
1.38 (1.01–1.66); 2 g TXA, 1.44 (1.04–2.08); 4 g TXA, 1.45
(1.14–1.81); Figure 2B). Despite this increase seen in frequency,
HLA-DR expression on CD14+CD16− monocytes was reduced
in all treatment groups, suggesting TXA dose had no effect on
monocyte HLA-DR expression at any time point (Figure 2C).
The fold change of HLA-DR expression on monocytes from
pre-TXA to 72 h post-TXA was similar between placebo [0.61
(0.51–0.82)], 2 g TXA [0.57 (0.47–0.75)], and 4 g TXA [0.57
(0.44–0.89)] study groups (p = 0.82, Figure 2D). These data
demonstrate that neither 2 g nor 4 g TXA dosing differentially
alters monocyte frequency or HLA-DR expression as compared
to placebo treatment. In addition, these data show that traumatic
injury leads to increased frequencies of circulating monocytes
with decreased HLA-DR levels by 3 days post injury. In addition
FIGURE 3 | TXA administration does not alter neutrophil frequencies or
phenotype. Placebo, n = 29; 2 g TXA, n = 24; 4 g TXA, n = 25. Statistical
differences between the 4 g TXA and placebo groups at each given time
point, as calculated via Kruskal-Wallis, are noted as follows: p < 0.05, *;
p > 0.05, not significant and not denoted on the graphical representation.
(A) The frequency of neutrophils found in total peripheral blood leukocytes at
T0 in all three treatment groups; data are represented as individual points with
median + IQR for error bars. (B) Fold change in neutrophil frequency over the
study period of 72 h. (C) CD11B MFI on neutrophils in all three treatment
(Continued)
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FIGURE 3 | Continued
groups at T0. (D) Fold change in CD11B MFI on neutrophils over the study
period of 72 h. (E) CD11C MFI on neutrophils in all three treatment groups at
T0. (F) Fold change in CD11C MFI on neutrophils over the study period of
72 h. (G) CD16 MFI on neutrophils in all three treatment groups at T0. (H) Fold
change in CD16 MFI on neutrophils over the study period of 72 h. (I) CD66B
MFI on neutrophils in all three treatment groups at T0. (J) Fold change in
CD66B MFI on neutrophils over the study period of 72 h. (K) CD62L MFI on
neutrophils in all three treatment groups at T0. (L) Fold change in CD62L MFI
on neutrophils over the study period of 72 h.
to HLA-DR, we also measured surface expression of CD86 and
CD16. We found that CD86 expression on classical monocytes
initially decreased, but changes in expression were similar across
all three treatment groups (data not shown). These changes were
not seen in non-classical monocytes, and there were little to no
alterations in CD16 expression on both monocyte populations
(data not shown).
As TXA inhibits the production of the pleiotropic immune
activator plasmin, we performed extensive immune and
hemostatic phenotyping in this study in order to identify if
TXA administration would lead to either a global or a unique
immune phenotype in traumatically injured patients. Looking at
other circulating myeloid cell types, we found no difference in
neutrophil frequencies at the time of or after TXA administration
(Figures 3A,B). Surface phenotyping of neutrophils revealed
little to no changes in surface expression of CD11B, CD11C,
CD16, or CD66B (Figures 3C–J). However, while CD62L MFI
was similar between all three groups at T0 (Figure 3K), there
was a statistically significant reduction in CD62L expression in
the 4 g TXA group [fold change: 0.73 (0.63–0.97)] compared
to the placebo group [0.97 (0.78–1.10)] at 24 h post treatment
(p = 0.034, Figure 3L). There were no profound differences
in eosinophil, basophil, or conventional dendritic cell (cDC)
populations either between treatment groups at T0, or between
treatment groups over the course of the study period (data not
shown, Supplementary Table S4).
A decrease in circulating lymphocytes resulted after traumatic
injury, and TXA administration did not change this effect
(Figure 4). CD4+ T cell frequencies were similar between
treatment groups at T0 (Figure 4A), and by T6 had decreased
roughly 50% in all three treatment groups (Figure 4B). This
reduction was maintained throughout the study period of 72 h
(Figure 4B). CD8+ T cells phenocopied CD4+ T cells, such
that there was a significant reduction (>50%) in CD8+ T cell
frequencies by T6, and this was similar between all treatment
groups, and maintained through the duration of the study period
(Figures 4C,D). Natural killer (NK) cell frequencies were similar
between treatment groups at T0, and by T6, NK cell frequencies
were reduced by roughly 80% (Figures 4E,F). These profiles were
similar between all three treatment groups at T6, T24, and T72.
Lastly, while B cell frequencies were reduced from T0 to T72
(Figures 4G,H), the reduction was not as severe as seen in both
T and NK cell compartments, and TXA administration did not
significantly alter B cell frequencies. In the first 24 h, there was
an increase in the frequency of circulating cDC, yet by 72 h post
treatment cDC levels had decreased to below baseline (T0) levels
FIGURE 4 | Traumatic injury, not TXA, decreases circulating lymphoid
populations. For T0, data are represented as individual points with
median + IQR for error bars. For all kinetic data, fold change was calculated
as [(frequency/MFI/concentration of a given population/analyte at the given
time | | T6,T24,T72| |) ÷ (frequency/MFI/concentration of the same
population/analyte at T0)]. Data are displayed as line graphs (fold change,
median + IQR). The dashed line placed at y = 1 represents T0, or baseline.
Placebo, n = 29; 2 g TXA, n = 24; 4 g TXA, n = 25. Statistical differences
between the 4 g TXA and placebo groups at each given time point, as
calculated via Kruskal–Wallis, are noted as follows: p > 0.05, not significant
and not denoted on the graphical representation. (A) The frequency of
CD4 + T cells found in total peripheral blood leukocytes at T0 in all three
treatment groups. (B) Fold change in frequency of CD4 + T cells found in total
peripheral blood leukocytes over the study period of 72 h. (C) The frequency
of CD8 + T cells found in total peripheral blood leukocytes at T0 in all three
treatment groups. (D) Fold change in frequency of CD8 + T cells found in total
peripheral blood leukocytes over the study period of 72 h. (E) The frequency
of NK cells found in total peripheral blood leukocytes at T0 in all three
treatment groups. (F) Fold change in frequency of NK cells found in total
peripheral blood leukocytes over the study period of 72 h. (G) The frequency
of B cells found in total peripheral blood leukocytes at T0 in all three treatment
groups. (H) Fold change in frequency of B cells found in total peripheral blood
leukocytes over the study period of 72 h.
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FIGURE 5 | TXA administration does not alter conventional or plasmacytoid
DC population changes in response to trauma. For T0, data are represented
as individual points with median + IQR for error bars. For all kinetic data, fold
change was calculated as [(frequency/MFI/concentration of a given
population/analyte at the given time | | T6,T24,T72| |) ÷
(frequency/MFI/concentration of the same population/analyte at T0)]. Data are
displayed as line graphs (fold change, median + IQR). The dashed line placed
at y = 1 represents T0, or baseline. Placebo, n = 29; 2 g TXA, n = 24; 4 g
TXA, n = 25. Statistical differences between the 4 g TXA and placebo groups
at each given time point, as calculated via Kruskal-Wallis, are noted as
follows: p > 0.05, not significant and not denoted on the graphical
representation. (A) The frequency of conventional dendritic cells (cDCs) found
in total peripheral blood leukocytes at T0 in all three treatment groups.
(B) Fold change in frequency of cDCs found in total peripheral blood
leukocytes over the study period of 72 h. (C) The frequency of plasmacytoid
dendritic cells (pDCs) found in total peripheral blood leukocytes at T0 in all
three treatment groups. (D) Fold change in frequency of pDCs found in total
peripheral blood leukocytes over the study period of 72 h.
(Figures 5A,B). There were no statistically significant differences
in cDC frequencies between treatment groups. Plasmacytoid
dendritic cell (pDC) populations were also reduced by roughly
two thirds within 6 h from baseline [placebo, 0.34 (0.15–0.58);
2 g TXA, 0.23 (0.14–0.45); 4 g TXA, 0.30 (0.14–0.56)], mimicking
the pattern seen in the T cell and NK cells compartments
and with little difference between placebo and TXA groups
(Figures 5C,D). Interestingly, we found a global reduction in
HLA-DR on B cells, CD14+CD16+ monocytes, cDCs, and pDCs
(Figures 6A–D) – similar to the phenotype of CD14+CD16−
monocytes seen in Figure 2. This reduction on HLA-DR was
independent of TXA dose. In contrast, CD86 expression (MFI)
was relatively maintained over the 72 h study period, with only
CD14+CD16− monocytes reducing CD86 levels by roughly half
at T6 and T24, but returning to T0 levels by T72 (Figures 6E–H).
Only a small fraction of the cytokines/chemokines assayed for
(6 of 21, see “Materials and Methods” section for full listing)
were found to be substantially altered from the baseline timepoint
(T0). IL-6 initially increased by∼5-fold at 6 h after baseline, then
decreased until 72 h post administration for all treatment groups
(Figure 7A). Notably, the fold decrease in IL-6 was significantly
less in the 4 g TXA group [1.36 (0.87–2.42)] compared to
the placebo group [0.46 (0.19–1.69)] at the 72 h time point
(p = 0.028; Figure 7B). While there were some differences in
absolute concentrations at certain time points, (Supplementary
Table S5), none of the other cytokines evaluated had a significant
fold change between study groups (data not shown). Lastly, we
found no differences in overall complement activation between
treatment groups; however, by T72, there was an approximate
doubling in classical complement activation (as determined by
CH50) in all three treatment groups Supplementary Figure S1).
We assessed multiple hemostatic parameters between the
study groups. Of all of the measurements performed, we found
a small number of significant and clinically relevant differences
related to TXA dosing. While fibrinogen (FIB) concentrations
were similar between groups at T0 (Figure 8A), by 24 h post-
treatment the fold change in FIB was significantly reduced in the
4 g TXA study group [1.69 (1.29–2.25)], compared to placebo
[2.38 (1.98–3.07)] (p = 0.023; Figure 8B). Moreover there was
a marked roughly 4-fold increase in FIB over the entire study
period for all three treatment groups (Figure 8B). We found no
difference in tPA between groups at T0, but that overall there was
an approximate 50% reduction in tPA levels over the course of
the study period, no matter the treatment group (Figures 8C,D).
The fold change seen in D-dimer levels was significantly smaller
in the 4 g TXA study group [0.83 (0.68–1.53)] compared to the
placebo group [1.58 (1.15–2.86)] at T6 (p = 0.006; Figures 8E,F).
We found that the clot maximum amplitude (MA), as measured
in PPP by TEG, was no different between treatment groups at T0
(Figure 8G). By T24, the placebo group had a greater increase in
MA as demonstrated by a 1.73-fold increase (Q1-Q3, 1.40–2.23)
in MA from T0, while the 4 g TXA group had only a 1.27-fold
increase (1.06–1.77) from T0 (p = 0.048, Figure 8H). However,
the median MA values at 24 h were not significantly different
between groups [placebo, 31.9 (27.5–35.4); 2 g TXA, 30.25 (24.8–
33.6); 4 g TXA, 28.4 (22.2–32.8); p = 0.283]. There were no
additional differences in hemostatic and endothelial parameters
measured between treatment groups (Supplementary Table S6).
Due to the comprehensive immune and hemostatic
phenotyping performed in this trial, we leveraged the entire
data set to see if we could identify signatures or trends that were
associated with TXA administration. We used all of the variables
listed in Supplementary Table S7 to generate correlation
matrices and subsequent heat maps (Figure 9A). We found that
in patients receiving placebo, the MFIs of CD86 and HLA-DR
on B cells, monocytes (CD14+CD16− and CD14+CD16+)
and DCs inversely correlated with the circulating levels of
GM-CSF, Fractalkine, IFNγ, IL-12p70, IL-17a, IL-1β, IL-2, IL-21,
IL-23, IL5, and IL-7 (arrowheads, Figure 9A, Supplementary
Figure S2). However, this correlation was diminished in patients
receiving 2 g or 4 g doses of TXA at early time points (T0, T6).
We also performed principal component analysis (variables used
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FIGURE 6 | Global reduction in HLA-DR and not CD86 expression in response to traumatic injury. For all kinetic data, fold change was calculated as
[(frequency/MFI/concentration of a given population/analyte at the given time | | T6,T24,T72| |) ÷ (frequency/MFI/concentration of the same population/analyte at
T0)]. Data are displayed as line graphs (fold change, median + IQR). The dashed line placed at y = 1 represents T0, or baseline. Placebo, n = 29; 2 g TXA, n = 24;
4 g TXA, n = 25. Statistical differences between the 4 g TXA and placebo groups at each given time point, as calculated via Kruskal–Wallis, are noted as follows:
p > 0.05, not significant and not denoted on the graphical representation. Fold change in HLA-DR MFI on (A) B cells, (B) CD14 + CD16 + non-classical monocytes,
(C) cDCs, and (D) pDCs over the 72 h study period. Fold change in CD86 MFI on (E) CD14 + CD16- monocytes, (F) CD14 + CD16 + non-classical monocytes, (G)
cDCs, and (H) pDCs over the 72 h study period.
in Supplementary Table S8) to determine the greatest source
of variance in our dataset. We first found that the kinetics of
trauma played an important role in dictating the immune and
hemostatic phenotype, as indicated by the time point clustering
seen in Figure 9B. Alternatively, the variance in the dataset
could not be explained by the use of TXA, as the 95% confidence
bands for each group in Figure 9C are relatively overlapping.
We subsequently examined TXA use at each distinct time point,
as time itself proved to impart a large degree of variance. We
observed again that the use of TXA was not informative as to the
variance in the immune and hemostatic profiles in these trauma
patients (Figure 9D).
DISCUSSION
Our trial was designed to determine the immunologic effects
of two different i.v. bolus doses of TXA in patients with
severe traumatic injury. This RCT is novel as it provides
early (<2 h from injury) immune phenotype information in
traumatically injured patients, and immune and hemostatic
phenotyping for up to 72 h following administration of TXA
or placebo. Our results indicate limited immunomodulatory
effects of TXA during the 72 h period post-treatment (as
determined by the phenotypic metrics we were able to assess), and
reduced fibrinolysis in response to higher doses of TXA. There
were no differences between treatment groups in biomarkers of
endothelial activation, the amount of blood products transfused
post-intervention, the incidence of MODS, or mortality. Plasmin
has been shown to have multiple effects on hemostatic, immune,
and endothelial function. However, our data demonstrate that
the immune and hemostatic phenotype induced by traumatic
injury greatly outweighs changes in function due to plasmin
inhibition by TXA.
The data from our trial indicates that HLA-DR expression
on monocytes was reduced approximately 40% (Figure 2), and
this was irrespective of the treatment group. TXA inhibition
of plasminogen has been shown to reduce the activation of
monocytes, neutrophils, and complement in animal trauma
models (50, 51). There is also evidence that when TXA is
used prophylactically for patients requiring cardiac surgery,
it enhances immune function, as evidenced by decreased
immune suppression and post-surgical infection rates (40). These
opposing data suggest that there may be a temporal and a disease
etiology component to TXA function, both of which dictate
the degree of the immune modulating effects of TXA. Draxler
et al. showed that in healthy volunteers, HLA-DR expression
was reduced on monocytes 24 h after TXA administration (40).
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FIGURE 7 | TXA administration increases circulating levels of IL-6. For T0,
data are represented as individual points with median + IQR for error bars. For
all kinetic data, fold change was calculated as [(frequency/MFI/concentration
of a given population/analyte at the given time | | T6,T24,T72| |) ÷
(frequency/MFI/concentration of the same population/analyte at T0)]. Data are
displayed as line graphs (fold change, median + IQR). The dashed line placed
at y = 1 represents T0, or baseline. Placebo, n = 29; 2 g TXA, n = 24; 4 g
TXA, n = 25. Statistical differences between the 4 g TXA and placebo groups
at each given time point, as calculated via Kruskal-Wallis, are noted as
follows: p < 0.05, *; p > 0.05, not significant and not denoted on
(Continued)
FIGURE 7 | Continued
the graphical representation. (A) IL-6 levels at T0 in all three treatment groups.
(B) Fold change in IL-6 levels over the study period of 72 h. (C) IL-8 levels at
T0 in all three treatment groups. (D) Fold change in IL-8 levels over the study
period of 72 h. (E) IL-4 levels at T0 in all three treatment groups. (F) Fold
change in IL-4 levels over the study period of 72 h. (G) IL-10 levels at T0 in all
three treatment groups. (H) Fold change in IL-10 levels over the study period
of 72 h. (I) Interferon-inducible T-cell alpha chemoattractant (ITAC/CXCL11)
levels at T0 in all three treatment groups. (J) Fold change in ITAC levels over
the study period of 72 h. (K) MIP1B levels at T0 in all three treatment groups.
(L) Fold change in MIP1B levels over the study period of 72 h.
With no underlying pathophysiology to bias the immune status,
perhaps it is easier to see the differences TXA can impart on
immune phenotype. However, after traumatic injury, there is a
dramatic reduction in HLA-DR expression on monocytes (52,
53). Moreover, our data show that there is a global reduction in
HLA-DR expression in response to traumatic injury, irrespective
of immune cell type (Figure 6), and that time after injury and
not TXA dose is responsible for variability in patient immune
phenotypes (Figure 9). Collectively, this evidence suggests that
perhaps the phenotypes incurred by trauma are more severe,
and outweigh any immune phenotype that would be induced by
TXA administration.
Our results also indicate that a 4 g dose of TXA was
associated with a relative reduction in neutrophil expression
of CD62L (Figure 3), which is important for neutrophil
adhesion and migration across endothelium (54, 55). CD62L
keeps neutrophils in the circulation as they cannot egress
(56), and is known to be shed almost instantaneously upon
cellular activation (54, 55). As CD62L levels in our study
did not significantly differ until 24 h post-TXA, and we
did not measure shed/soluble CD62L, we cannot directly
determine whether the TXA-induced differences in CD62L
were indicative of neutrophil activation. One study in healthy
humans receiving i.v. bolus injections of lipopolysaccharide
(LPS, 4 ng/kg) established that a 2 g bolus of TXA 30 min
prior to LPS injection did not alter neutrophil activation,
CD62L expression, or degranulation (57). In contrast, other
studies in trauma populations have demonstrated that CD62L
expression is decreased in response to traumatic injury alone.
In 2017, Hazeldine et al. found CD62L expression was
decreased by 15% at 72 h after traumatic injury (52). More
recently, machine learning was used to identify molecular
signatures associated with MODS in traumatically injured
patients. In this study, they found that decreases in CD62L
expression on fMLF-activated neutrophils, neutrophil CD63
expression, and monocyte frequency were associated with
MODS development (58). These data again highlight that the
immune modulating effects of TXA are most likely highly
dependent on disease etiology and timing of TXA administration
(pre- or post-insult). Moreover, assessment of neutrophil
function, such as respiratory burst in response to priming and
degranulation, would be more informative regarding the true
immunomodulatory nature of TXA.
Our results revealed increased plasma levels of IL-6 at 72 h
post TXA administration compared to placebo (Figure 7).
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FIGURE 8 | A higher dose of TXA decreases circulating D-dimer levels early
after administration. For T0, data are represented as individual points with
median + IQR for error bars. For all kinetic data, fold change was calculated
as [(frequency/MFI/concentration of a given population/analyte at the given
time | | T6,T24,T72| |) ÷ (frequency/MFI/concentration of the same
population/analyte at T0)]. Data are displayed as line graphs (fold change,
median + IQR). The dashed line placed at y = 1 represents T0, or baseline.
Placebo, n = 29; 2 g TXA, n = 24; 4 g TXA, n = 25. Statistical differences
between the 4 g TXA and placebo groups at each given time point, as
calculated via Kruskal-Wallis, are noted as follows: p < 0.01, **; p < 0.05, *;
p > 0.05, not significant and not denoted on the graphical representation.
(A) Fibrinogen (FIB, mg/dL) levels at T0 in all three treatment groups (placebo,
n = 31; 2 g TXA, n = 25; 4 g TXA, n = 25). (B) Fold change in FIB levels over
the study period of 72 h (placebo, n = 17; 2 g TXA, n = 13; 4 g TXA, n = 10).
(C) Tissue plasminogen activator (tPA, pg/mL) levels at T0 in all three
treatment groups (placebo, n = 31; 2 g TXA, n = 25; 4 g TXA, n = 25). (D) Fold
change in tPA levels over the study period of 72 h (placebo, n = 28; 2 g TXA,
n = 24; 4 g TXA, n = 20). (E) D-dimer (D-Di, µg/mL) levels at T0 in all three
treatment groups (placebo, n = 31; 2 g TXA, n = 25; 4 g TXA, n = 25). (F) Fold
change in D-Di levels over the study period of 72 h (placebo, n = 30; 2 g TXA,
n = 25; 4 g TXA, n = 25). (G) Maximum amplitude (MA, mm) levels at T0 in all
three treatment groups (placebo, n = 30; 2 g TXA, n = 25; 4 g TXA, n = 22).
(H) Fold change in MA over the study period of 72 h (placebo, n = 30; 2 g
TXA, n = 23; 4 g TXA, n = 19).
A similar increase in inflammatory markers was found in
orthopedic surgery patients receiving TXA during active bleeding
(38). In cardiac surgery patients receiving TXA prophylactically,
Draxler et al. demonstrated that IL-6 levels were similar between
placebo and TXA treated patients on post-operative day 1 (40).
These data suggest that both the baseline immunologic state of
the patient and timing of TXA administration may dictate TXA-
mediated IL-6 induction or suppression. For example, when TXA
is given prophylactically, before bleeding occurs, the patient is at
less risk of being in a hyperinflammatory state, and leukocytes
are not “primed” to respond to a second stimulus. Conversely,
when TXA is given to an actively bleeding patient, the patient’s
immune system is activated and may respond with increased IL-6
production in this setting.
Tranexamic acid inhibits plasminogen activation and plasmin
activity to prevent clot lysis. In our trial, there were clinically
relevant differences in D-dimer concentrations at 6 h (Figure 8
and Supplementary Table S3), reflecting the antifibrinolytic
effect of TXA between study groups. Fibrinogen concentrations
between study groups at 24 h were statistically different,
but the differences do not appear to be clinically significant
upon examination of the absolute values for each of these
parameters (Figure 8 and Supplementary Table S3). Measures
of procoagulant activity, including thrombin-antithrombin
complex (TAT), prothrombin fragment 1 and 2 (PF 1 and 2), and
viscoelastic testing with thromboelastography (TEG) clot time (R
time) and plasma clot strength were all similar between groups.
While the median fold change in maximum amplitude, or MA,
in the 4 g TXA group was significantly decreased compared to
the placebo group at 24 h post-TXA (Figure 8), the median MA
values at 24 h were not significantly different between groups. The
transiently lower MA in the 4 g TXA group may be explained
by the lesser increase in FIB at 24 h. Lastly, there was a trend
that approached significance regarding the incidence of TE with
respect to TXA dose. Previous trials of TXA use in trauma
populations have not reported an increased risk of TE (14, 15).
In contrast to our study, these trials did not use active Duplex
screening for TE, thereby potentially underreporting TE events.
However, our results are consistent with the HALT-IT study, an
RCT on TXA use in 12,000 adults with gastrointestinal bleeding
that reported an increase in TE when TXA is used in this
population (59).
Endothelial effects of TXA have been examined in in vitro
models of reperfusion injury indicating preservation of the
glycocalyx (60, 61). The field of clinical monitoring of endothelial
dysfunction has been limited to assessing reactive hyperemia (62),
therefore the use of SDC1 as a potential biomarker of endothelial
injury has been of great interest. Our study indicates that there
was no difference in circulating VWF (a sign of endothelial
activation and Weibel-Palade body mobilization) or SDC1 (shed
in response to endothelial activation or damage) concentrations
between TXA-treated and placebo groups during the 72 h
post TXA administration (data not shown, Supplementary
Table S6). Lastly, there were no differences in mortality
among treatment groups, although there was a dose-dependent
numerical reduction in 28-day mortality for patients treated with
TXA. Previous studies reporting reduced mortality when TXA
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FIGURE 9 | The effects of trauma, and not of TXA administration, impart the greatest impact on immune and hemostatic phenotypes in traumatically injured bleeding
patients. (A) Correlation matrices at each time point for each study group were built using the variables listed in Supplementary Table S7. Positive correlation is
denoted in blue, while a negative correlation is denoted in red. Principal component analysis (PCA) labeled by (B) sampling time point (“timepoint_event_type”; T0,
T6, T24, and T72; n = 283), (C) treatment group (“txa_group”; Placebo, 2 g TXA, 4 g TXA; n = 283), or (D) at a given time point by treatment group. For PCA,
confidence ellipses are set at 95%.
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was administered after severe bleeding included far more patients
than our study (14, 63, 64).
This trial is the first trauma-based RCT to have blood drawn
prior to TXA administration, and as such provides a unique
insight into the immune and hemostatic profiles early after
trauma but prior to TXA administration. However, there are
several limitations of this trial. First, it was not possible to assess
leukocyte function by ex vivo stimulation, cytokine production,
migration, or other functional readouts due to the lack of
24 h availability of laboratory-based research staff. This would
have allowed for a more thorough analysis of the immune
consequences of TXA in this population. Second, the sample
size of the trial was inadequate to assess sex as a biological
variable, as well as effects on clinical outcomes such as organ
failure and mortality. Third, the high frequency of penetrating
injury may reduce generalization of these results to populations
with blunt injury. Fourth, ICU free days were calculated using a
30 day model, even though follow-up was only through hospital
discharge. Fifth, the inability to serially obtain viscoelastic
measures at this trauma center from WB samples impaired the
ability to examine hemostatic function in full. Lastly, we were
only able to measure classical complement activation, and not
activation of the alternative or lectin pathways.
CONCLUSION
In conclusion, in this RCT in patients with primarily penetrating
traumatic injuries, 2 and 4 g i.v. bolus dosing of TXA had minimal
immunomodulatory and hemostatic effects.
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